The pharmacovigilance market is anticipated to increase, from US$ 6.87 billion in 2023 to US$ 23.31 billion in 2033. According to FMI, the market is expected to expand at a CAGR of 13% over the course of the projected period.
As a result of the development of chronic illnesses, which necessitates the use of pharmacovigilance more frequently, there is an increased demand for novel pharmaceuticals that are created through meticulous clinical research.
It is anticipated that demand for pharmacovigilance services is likely to increase, as adverse drug reactions (ADRs) happen more frequently. Additionally, a combination of rising expectations for drug safety and rising patient consumption of medications is the main driver of the pharmacovigilance market expansion during the forecast period.
Moreover, clinicians must perform comprehensive tests and data analysis to assure minimal adverse effects, which forces big pharmaceutical companies to work with renowned pharmacovigilance service providers.
| Attributes | Details |
|---|---|
| Historical Value (2022) | US$ 6.28 billion |
| Current Year Value (2023) | US$ 6.87 billion |
| Expected Forecast Value (2033) | US$ 23.31 billion |
| Historical CAGR (2018 to 2022) | 7.9% |
| Projected CAGR (2023 to 2033) | 13% |
Furthermore, the advent of COVID-19 has given pharmaceutical companies a variety of opportunities to create novel vaccines, resulting at the beginning of multiple clinical trials. This function now makes it easier to enter the pharmacovigilance market, which is the most important stage of any medicine development process.
Therefore, during the anticipated time, the growth of the pharmacovigilance market is likely to be supported by such favorable initiatives.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Drivers | As a result of increased public awareness of OTC drug adverse effects; there is a greater need for safer drugs. This feature is anticipated to accelerate the demand for pharmacovigilance due to the monitoring of medications that are readily available on the market for potential adverse drug responses. |
|---|---|
| Example | Every year, the Uppsala Monitoring Centre (UMC) runs a social media campaign to raise patient and public awareness of the importance of reporting suspected ADRs and the safe use of medications. |
| Drivers | Credible information on medicines, their correct usage, side effects, and other topics are transmitted more widely thanks to government initiatives, programs, and pharmaceutical firms' awareness campaigns. |
|---|---|
| Example | The American Society of Pharmacovigilance officially launched a national awareness campaign in March 2021 to encourage people who have experienced adverse drug events to share their experiences and foster community support, while praising organizations and healthcare professionals for talking about how they can support medication safety. |
| Drivers | Regarding time restrictions and the facilities that an outsourced service may supply, outsourcing offers clear benefits to manufacturing organizations. Additionally, outsourcing permits businesses to customize services in accordance with their needs, accelerating the evaluation process. |
|---|---|
| Example | On International Patient Safety Day in 2019, Bayer unveiled the SafeTrack digital application, which allows users to report negative incidents. The program is a simple, practical internet tool that enables prompt reporting of an AE. |
Lack of Awareness:
Inconsistent reporting is a result of patients' lack of knowledge regarding adverse events (AE). The patient typically becomes worried and reports all of their symptoms as an adverse event (AE). But not all reported adverse events (AEs) are necessarily serious, which forces committees in pharmaceutical firms to make bad decisions that result in the drug's withdrawal.
The necessary software, services, and training are missing in low- and middle-income nations for these specialized services. In addition, little is being done by governments and pharmaceutical firms to raise awareness of AE reporting. The pharmacovigilance market expansion in low- and middle-income nations is predicted to be constrained by these issues.
Data Security:
Moreover, the pharmacovigilance market may see a slowdown during the projected period due to issues like the high risk associated with data security, the absence of global regulatory harmonization, and the lack of data standardization for adverse event collecting.
| Segment | 2022 Value Share in Global Market |
|---|---|
| Phase IV | 75.1% |
| Spontaneous Reporting | 31.1% |
With a revenue share of more than 75.1% in 2022, the phase IV (post-marketing) segment took the whole market by storm.
These treatments serve as an extra layer of safety for the medications undergoing clinical trials. Due to intense drug testing on a wide demographic patient base of the highest significance following the commercialization of the drug, it is envisaged that the data gathered and evaluated during this stage is of the highest relevance.
Phase-IV clinical trials have gained substantial importance in the pharmacovigilance market due to their role in post-market surveillance. Conducted after a drug's approval, these trials monitor its safety and efficacy in a broader patient population, offering real-world evidence beyond controlled settings. They are vital for identifying rare adverse events and interactions with different patient profiles, leading to better risk management and patient safety.
Phase-IV trials provide data on a drug's comparative effectiveness, supporting healthcare decision-making and regulatory compliance. They contribute to drug lifecycle management by facilitating label updates, new indications, and market access negotiations. Moreover, Phase-IV trials play a critical role in generating real-world data and evidence, complementing traditional clinical trial information and helping assess a drug's cost-effectiveness. Hence, Phase-IV clinical trials have become indispensable for continuous drug evaluation, ensuring safer and more effective healthcare practices.
In 2022, spontaneous reporting accounted for the biggest share with almost 31.1%.
This is because the technique is widely used in the detection of novel, severe, and uncommon ADRs and is both effective and affordable. The extensive use of monitoring reports produced using this methodology by the pharmaceutical industry and regulatory bodies is another factor contributing to the segment's rapid expansion.
Spontaneous reporting plays a vital role in the pharmacovigilance market since it enables the early detection of adverse events related to medications and medical products. This ensures timely interventions to protect patient safety. Regulatory compliance mandates pharmaceutical companies to implement robust pharmacovigilance systems, including effective spontaneous reporting mechanisms. By adhering to these regulations, companies demonstrate their commitment to public health and enhance their market reputation.
The continuous growth of drug pipelines necessitates improved pharmacovigilance capabilities. This leads to investments in technologies and data analytics that streamline spontaneous reporting processes. Additionally, global harmonization efforts in pharmacovigilance standards drive companies to invest in infrastructure and capabilities to meet international requirements. Furthermore, the industry's shift toward patient-centric care has elevated the importance of listening to patients' experiences and concerns. Spontaneous reporting empowers patients to participate actively in drug safety by reporting adverse events they encounter.
Principal Consultant
North America held the largest revenue share of over 30.0% in 2021 owing to the presence of key pharmaceutical and medical devices players, contributing to the overall revenue in this region. The rising level of drug abuse and associated adverse drug reactions is a leading cause of morbidity and death.
This acts as a high-growth rendering factor for the pharmacovigilance market in North America. Rising investment in novel drug development by major players is also anticipated to propel regional market growth.
| Country | United States |
|---|---|
| 2022 Value Share in Global Market | 30.9% |
The United States has one of the leading pharmaceutical markets globally, making it a crucial region for pharmacovigilance activities. The country's stringent regulatory framework and a strong emphasis on patient safety have fueled the market growth. The increasing number of adverse drug events and drug recalls has led pharmaceutical companies and regulatory authorities to prioritize pharmacovigilance activities. The United States Food and Drug Administration (FDA) plays a vital role in pharmacovigilance, setting strict guidelines for drug safety monitoring and post-market surveillance. The FDA's oversight and commitment to patient safety have contributed to shaping the pharmacovigilance practices in the country. The United States has seen a growing focus on patient-centric pharmacovigilance, where patient-reported outcomes and experiences are actively sought and valued. As the pharmaceutical industry continues to innovate and introduce new therapies, the importance of robust pharmacovigilance practices is likely to only grow in ensuring the safe use of medications in the United States.
Currently, a number of clinical trials are anticipated to be carried out to evaluate the effectiveness of different medication candidates, offering up new growth opportunities for UK-based providers of pharmacovigilance solutions.
The London Trials, which are scheduled to start in the summer of 2021, is an example. The Hammersmith Medicines Research organization is managing these trials.
| Country | Value CAGR (2023 to 2033) |
|---|---|
| United Kingdom | 12.1% |
| Country | 2022 Value Share in Global Market |
| Germany | 6.9% |
The increasing adoption of personalized medicine in the United Kingdom has led to a surge in the number of medications tailored to individual patient profiles. This trend necessitates rigorous pharmacovigilance efforts to monitor patient responses and identify any adverse reactions specific to certain genetic groups. Healthcare stakeholders in the United Kingdom are increasingly relying on real-world evidence to complement clinical trial data. Pharmacovigilance initiatives are leveraging RWE to gain deeper insights into drug safety and efficacy in real-world settings, thereby improving patient outcomes. The expanding pharmaceutical sector in the United Kingdom, driven by research and development activities, has increased the number of drugs reaching the market. This growth has amplified the demand for pharmacovigilance services to ensure comprehensive drug safety monitoring.
As a leader in innovation and technology, Germany has adopted advanced pharmacovigilance tools such as artificial intelligence, machine learning, and big data analytics to streamline adverse event reporting and signal detection. This has improved efficiency and accuracy in identifying potential safety issues with drugs. The rise in biopharmaceutical companies in Germany has fueled the need for pharmacovigilance services. Biologics require specialized safety monitoring, leading to an increased demand for expert pharmacovigilance support. Germany boasts a robust and well-organized healthcare system. Its comprehensive network of hospitals, clinics, and healthcare professionals ensures timely and accurate reporting of adverse drug reactions. This is contributing to the effectiveness of pharmacovigilance efforts.
Due to the abundance of outsourcing companies, Asia Pacific is anticipated to experience the quickest CAGR during the projection period. Improvements in productivity, cost-effectiveness, and resource sharing, as a result, are predicted to drive up regional demand for pharmacovigilance in the ensuing years.
The regional market is also being driven by expanding investments, rising spending among patients, and supportive government activities for satisfying population needs.
| Country | Value CAGR (2023 to 2033) |
|---|---|
| China | 16.8% |
| India | 15.4% |
| Country | 2022 Value Share in Global Market |
| Japan | 5.1% |
As one of the world's leading pharmaceutical markets, China has witnessed significant growth in its pharmacovigilance sector. The pharmaceutical industry's rapid growth in China directly impacts the pharmacovigilance market. Increased drug production and consumption necessitate more stringent pharmacovigilance measures. China has embraced technological innovations in healthcare, including AI and big data analytics. These advancements have enabled faster and more accurate identification of ADRs, improving overall drug safety surveillance. China's rich history of traditional medicine has led to unique challenges in pharmacovigilance. The coexistence of traditional and modern medicines requires a tailored approach to monitoring and reporting adverse events. The growth of e-commerce in China has also affected pharmacovigilance efforts. It has opened up new channels for the sale of pharmaceutical products, necessitating robust monitoring to detect and address potential safety issues.
The pharmacovigilance market in India has experienced significant growth in recent years. As India's pharmaceutical industry continues to grow, the importance of pharmacovigilance becomes even more effective in maintaining drug safety standards. With an increasing population and growing middle class, the demand for quality healthcare services in India has surged. As a result, the market has witnessed higher demand for drug safety monitoring and reporting. India has emerged as a preferred destination for global pharmaceutical companies to outsource their Pharmacovigilance processes. The availability of a skilled workforce and cost-effectiveness have made India an attractive outsourcing hub for Pharmacovigilance services. India has a significant market for over-the-counter drugs. Since some OTC drugs may not require a prescription, monitoring their adverse effects can be challenging. Pharmacovigilance efforts need to encompass both prescription and non-prescription drugs.
Japan has a strong healthcare infrastructure and a well-established reporting system for adverse drug reactions. The Japanese population is proactive in reporting ADRs, which has led to an increase in the number of pharmacovigilance activities. Many pharmaceutical companies in Japan are outsourcing pharmacovigilance services to specialized third-party providers. This trend is driven by the need to focus on core competencies and ensure compliance with stringent regulations. Japan possesses one of the most prominent aging populations globally. As the elderly are more susceptible to adverse drug reactions, there is a growing focus on monitoring drug safety in this demographic. With the increasing influence of technology, the market in Japan is expected to remain dynamic and essential for ensuring drug safety during the forecast period.
Service providers from many regions are developing cutting-edge technologies to support the pharmacovigilance business. The technology comprises real-time products, AI-based solutions, and fresh drugs in the pipeline.
For instance:
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The patent expiration of branded pharmaceuticals is encouraging new clinical trials to discover new candidates, which is causing prominent companies in the pharmacovigilance market to see an improvement in their revenue prospects. Some market participants use collaborations with top pharmaceutical companies as a key strategy.
Collaboration and Business Services
Key players like Accenture, Cognizant, and IQVIA are benefiting from improved pharmacovigilance management.
Market players are continuously developing safety services to increase the adoption of pharmacovigilance services while concentrating on technological progress. Analytics, AI, and automation have increased the effectiveness of the businesses offering pharmacovigilance services. Automation, machine learning, and artificial intelligence are likely to soon lead to a paradigm shift in pharmacovigilance due to their sophisticated technological capabilities.
Cognizant Technology Solutions, which offers a full range of patient safety services, was recently recognized as one of the top businesses in the pharmacovigilance market in April 2021. This follows the company's ongoing efforts to improve its technologically enabled products in order to better assist clients with their digital transformation.
The market is expanding further due to rising Research and Development and the rising adoption of new technologies in clinical research. For instance, industry players like IQVIA and PRA Health Sciences are expected to boost demand in the upcoming years by incorporating virtual services into the clinical trial protocol.
Rising partnerships in the industry between software suppliers and pharmaceutical firms are also anticipated to fuel the demand for pharmacovigilance.
For instance, in November 2021, Deloitte and Sanofi worked together to develop ConvergeHEALTH Safety, a next-generation adverse events case intake platform powered by artificial intelligence (AI). This platform revolutionizes pharmacovigilance and tackles some of the most urgent operational safety issues facing the sector.
Additionally, eco-pharmacovigilance has gained prominence recently and is essential for reducing the likelihood that pharmaceutical pollutants affect the environment. As a result, pharmaceutical firms might use pharmacovigilance services to lessen environmental pollution, fueling the market's expansion.
There is a significant demand for enhanced manufacturing processes, pharmacovigilance, clinical data management, streamlined Research and Development, and medical writing as a result of the market competition for the introduction of novel compounds. For EUR 1.5 million in 2020, the UK government collaborated with the American business Genpact to create an artificial intelligence tool for screening vaccine adverse drug response (ADR) data.
Chronic illness patients are the key consumers of the global market.
Phase 4 is poised to stay attractive, projecting a significant CAGR by 2033.
The market is estimated to secure a valuation of US$ 6.87 billion in 2023.
The market is estimated to reach US$ 23.31 billion by 2033.
The hospital sector holds high revenue potential.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Phase of Drug Development 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Phase of Drug Development, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Phase of Drug Development, 2023 to 2033 5.3.1. Preclinical Studies 5.3.2. Phase I 5.3.3. Phase II 5.3.4. Phase III 5.3.5. Phase IV 5.4. Y-o-Y Growth Trend Analysis By Phase of Drug Development, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Phase of Drug Development, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type of Methods 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Type of Methods, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type of Methods, 2023 to 2033 6.3.1. Spontaneous Reporting 6.3.2. Intensified ADR Reporting 6.3.3. Targeted Spontaneous Reporting 6.3.4. Cohort Event Monitoring 6.3.5. EHR Mining 6.4. Y-o-Y Growth Trend Analysis By Type of Methods, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Type of Methods, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Service Type Provider 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Service Type Provider , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Service Type Provider , 2023 to 2033 7.3.1. In-house Pharmacovigilance 7.3.2. Contract Outsourcing 7.4. Y-o-Y Growth Trend Analysis By Service Type Provider , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Service Type Provider , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. South Asia and Pacific 8.3.6. East Asia 8.3.7. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Phase of Drug Development 9.2.3. By Type of Methods 9.2.4. By Service Type Provider 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Phase of Drug Development 9.3.3. By Type of Methods 9.3.4. By Service Type Provider 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Phase of Drug Development 10.2.3. By Type of Methods 10.2.4. By Service Type Provider 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Phase of Drug Development 10.3.3. By Type of Methods 10.3.4. By Service Type Provider 10.4. Key Takeaways 11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. UK 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Western Europe 11.2.2. By Phase of Drug Development 11.2.3. By Type of Methods 11.2.4. By Service Type Provider 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Phase of Drug Development 11.3.3. By Type of Methods 11.3.4. By Service Type Provider 11.4. Key Takeaways 12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Poland 12.2.1.2. Russia 12.2.1.3. Czech Republic 12.2.1.4. Romania 12.2.1.5. Rest of Eastern Europe 12.2.2. By Phase of Drug Development 12.2.3. By Type of Methods 12.2.4. By Service Type Provider 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Phase of Drug Development 12.3.3. By Type of Methods 12.3.4. By Service Type Provider 12.4. Key Takeaways 13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Bangladesh 13.2.1.3. Australia 13.2.1.4. New Zealand 13.2.1.5. Rest of South Asia and Pacific 13.2.2. By Phase of Drug Development 13.2.3. By Type of Methods 13.2.4. By Service Type Provider 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Phase of Drug Development 13.3.3. By Type of Methods 13.3.4. By Service Type Provider 13.4. Key Takeaways 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Phase of Drug Development 14.2.3. By Type of Methods 14.2.4. By Service Type Provider 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Phase of Drug Development 14.3.3. By Type of Methods 14.3.4. By Service Type Provider 14.4. Key Takeaways 15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Phase of Drug Development 15.2.3. By Type of Methods 15.2.4. By Service Type Provider 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Phase of Drug Development 15.3.3. By Type of Methods 15.3.4. By Service Type Provider 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Phase of Drug Development 16.1.2.2. By Type of Methods 16.1.2.3. By Service Type Provider 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Phase of Drug Development 16.2.2.2. By Type of Methods 16.2.2.3. By Service Type Provider 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Phase of Drug Development 16.3.2.2. By Type of Methods 16.3.2.3. By Service Type Provider 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Phase of Drug Development 16.4.2.2. By Type of Methods 16.4.2.3. By Service Type Provider 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Phase of Drug Development 16.5.2.2. By Type of Methods 16.5.2.3. By Service Type Provider 16.6. UK 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Phase of Drug Development 16.6.2.2. By Type of Methods 16.6.2.3. By Service Type Provider 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Phase of Drug Development 16.7.2.2. By Type of Methods 16.7.2.3. By Service Type Provider 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Phase of Drug Development 16.8.2.2. By Type of Methods 16.8.2.3. By Service Type Provider 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Phase of Drug Development 16.9.2.2. By Type of Methods 16.9.2.3. By Service Type Provider 16.10. Poland 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Phase of Drug Development 16.10.2.2. By Type of Methods 16.10.2.3. By Service Type Provider 16.11. Russia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Phase of Drug Development 16.11.2.2. By Type of Methods 16.11.2.3. By Service Type Provider 16.12. Czech Republic 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Phase of Drug Development 16.12.2.2. By Type of Methods 16.12.2.3. By Service Type Provider 16.13. Romania 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Phase of Drug Development 16.13.2.2. By Type of Methods 16.13.2.3. By Service Type Provider 16.14. India 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Phase of Drug Development 16.14.2.2. By Type of Methods 16.14.2.3. By Service Type Provider 16.15. Bangladesh 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Phase of Drug Development 16.15.2.2. By Type of Methods 16.15.2.3. By Service Type Provider 16.16. Australia 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Phase of Drug Development 16.16.2.2. By Type of Methods 16.16.2.3. By Service Type Provider 16.17. New Zealand 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Phase of Drug Development 16.17.2.2. By Type of Methods 16.17.2.3. By Service Type Provider 16.18. China 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Phase of Drug Development 16.18.2.2. By Type of Methods 16.18.2.3. By Service Type Provider 16.19. Japan 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Phase of Drug Development 16.19.2.2. By Type of Methods 16.19.2.3. By Service Type Provider 16.20. South Korea 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Phase of Drug Development 16.20.2.2. By Type of Methods 16.20.2.3. By Service Type Provider 16.21. GCC Countries 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Phase of Drug Development 16.21.2.2. By Type of Methods 16.21.2.3. By Service Type Provider 16.22. South Africa 16.22.1. Pricing Analysis 16.22.2. Market Share Analysis, 2022 16.22.2.1. By Phase of Drug Development 16.22.2.2. By Type of Methods 16.22.2.3. By Service Type Provider 16.23. Israel 16.23.1. Pricing Analysis 16.23.2. Market Share Analysis, 2022 16.23.2.1. By Phase of Drug Development 16.23.2.2. By Type of Methods 16.23.2.3. By Service Type Provider 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Phase of Drug Development 17.3.3. By Type of Methods 17.3.4. By Service Type Provider 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Accenture Plc. 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Bristol-Myers Squibb 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Clinquest Group B.V. 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Cognizant Technology Solutions 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Covance Inc. 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. F. Hoffmann-La Roche Ltd. 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. GlaxoSmithKline Plc. 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. ICON Plc 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. iGATE Corporation 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. iMED Global Corporation 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 18.1.11. inVentiv Health Inc. 18.1.11.1. Overview 18.1.11.2. Product Portfolio 18.1.11.3. Profitability by Market Segments 18.1.11.4. Sales Footprint 18.1.11.5. Strategy Overview 18.1.11.5.1. Marketing Strategy 18.1.12. Novartis AG 18.1.12.1. Overview 18.1.12.2. Product Portfolio 18.1.12.3. Profitability by Market Segments 18.1.12.4. Sales Footprint 18.1.12.5. Strategy Overview 18.1.12.5.1. Marketing Strategy 18.1.13. PAREXEL International Corporation 18.1.13.1. Overview 18.1.13.2. Product Portfolio 18.1.13.3. Profitability by Market Segments 18.1.13.4. Sales Footprint 18.1.13.5. Strategy Overview 18.1.13.5.1. Marketing Strategy 18.1.14. Pfizer Inc. 18.1.14.1. Overview 18.1.14.2. Product Portfolio 18.1.14.3. Profitability by Market Segments 18.1.14.4. Sales Footprint 18.1.14.5. Strategy Overview 18.1.14.5.1. Marketing Strategy 18.1.15. Pharmaceutical Product Development LLC. (PPD) 18.1.15.1. Overview 18.1.15.2. Product Portfolio 18.1.15.3. Profitability by Market Segments 18.1.15.4. Sales Footprint 18.1.15.5. Strategy Overview 18.1.15.5.1. Marketing Strategy 18.1.16. PRA Health Sciences Inc. 18.1.16.1. Overview 18.1.16.2. Product Portfolio 18.1.16.3. Profitability by Market Segments 18.1.16.4. Sales Footprint 18.1.16.5. Strategy Overview 18.1.16.5.1. Marketing Strategy 18.1.17. Quintiles Transnational Holdings Inc. 18.1.17.1. Overview 18.1.17.2. Product Portfolio 18.1.17.3. Profitability by Market Segments 18.1.17.4. Sales Footprint 18.1.17.5. Strategy Overview 18.1.17.5.1. Marketing Strategy 18.1.18. Sanofi SA 18.1.18.1. Overview 18.1.18.2. Product Portfolio 18.1.18.3. Profitability by Market Segments 18.1.18.4. Sales Footprint 18.1.18.5. Strategy Overview 18.1.18.5.1. Marketing Strategy 18.1.19. Synowledge LLC 18.1.19.1. Overview 18.1.19.2. Product Portfolio 18.1.19.3. Profitability by Market Segments 18.1.19.4. Sales Footprint 18.1.19.5. Strategy Overview 18.1.19.5.1. Marketing Strategy 18.1.20. Wipro Ltd. 18.1.20.1. Overview 18.1.20.2. Product Portfolio 18.1.20.3. Profitability by Market Segments 18.1.20.4. Sales Footprint 18.1.20.5. Strategy Overview 18.1.20.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Pharmacovigilance Market
